Your search for baricitinib returned 27 results

Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.

The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.

The update was based on data from the COV-BARRIER study.

Results from 2 studies show statistically significant improvement in scalp hair regrowth with baricitinib, a JAK inhibitor.

Findings showed that the trial did not meet statistical significance on the primary endpoint.

Both doses of baricitinib met the primary end point, demonstrating statistically significant improvement in scalp hair regrowth compared with placebo.

The EUA was granted based on data from the phase 3 ACTT-2 trial, which was conducted by the NIAID.

The ACTT-2 study began on May 8 and included more than 1000 patients.

Baricitinib, a JAK inhibitor, is currently approved in the US for rheumatoid arthritis.

Updated on 6/16 While no specific treatment for coronavirus disease 2019 (COVID-19) is currently available, several therapies are being investigated globally.*    AB201 (ARCA biopharma): a selective inhibitor of tissue factor being developed as a potential treatment for COVID associated coagulopathy. Clinical testing is expected to begin in the second half of 2020. Acalabrutinib (AstraZeneca): a…